{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:31:30Z","timestamp":1794940290671,"version":"4.9.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["R01 EY033794-01"],"award-info":[{"award-number":["R01 EY033794-01"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["R01 EY032561"],"award-info":[{"award-number":["R01 EY032561"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Investigate risk factors for short-term reactivation of retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) therapy and determine safety and efficacy of repeat injections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective chart review study of patients screened for ROP as inpatients between 2013 and 2023 who received IVR within the UCLA health care system. Primary outcomes were rates and timing of short-term ROP reactivation, defined as repeat worsening of ROP to stage 2 or 3 before 52 weeks postmenstrual age, as well as risk factors for reactivation. Other outcomes included adverse events and rates of reactivation after a second intravitreal injection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eighty-two eyes of 43 patients received primary IVR 0.25 mg\/0.025 cc for type 1 ROP. Thirteen patients (22 eyes) (30.2% of patients, 26.8% of eyes) developed short-term reactivation an average of 7.2 weeks \u00b1 1.7 weeks after treatment. Increased reactivation risk was associated with zone I disease (odds ratio 6.23, 95% CI, 1.35\u201328.7, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.019), lower postmenstrual age at first injection (odds ratio 1.64, 95% CI, 1.19\u20132.26; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003), and lower gestational age at birth (odds ratio 1.80, 95% CI, 1.04\u20133.13, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.037). Of the 13 patients that received repeat injections, five required laser treatment for a second reactivation (11.6% of patients receiving IVR). No eyes developed retinal vascular occlusion, endophthalmitis, or cataract.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Repeat injections may be required after primary IVR for aggressive ROP. Repeat IVR treatment for ROP is effective and poses few ophthalmic adverse events, although additional reactivation remains a risk.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004206","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T18:00:05Z","timestamp":1721325605000},"page":"1945-1951","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["SHORT-TERM REACTIVATION OF RETINOPATHY OF PREMATURITY AFTER PRIMARY RANIBIZUMAB TREATMENT"],"prefix":"10.1097","volume":"44","author":[{"given":"Jason","family":"Strawbridge","sequence":"first","affiliation":[{"name":"Division of Retina and Vitreous Diseases, Stein and Doheny Eye Institutes, University of California Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Y.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Retina and Vitreous Diseases, Stein and Doheny Eye Institutes, University of California Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Gundlach","sequence":"additional","affiliation":[{"name":"Division of Retina and Vitreous Diseases, Stein and Doheny Eye Institutes, University of California Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Gillespie","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmouta","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Khitri","sequence":"additional","affiliation":[{"name":"Division of Pediatric Ophthalmology and Strabismus, Stein and Doheny Eye Institutes, University of California Los Angeles, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Chu","sequence":"additional","affiliation":[{"name":"Division of Neonatology and Developmental Biology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Tsui","sequence":"additional","affiliation":[{"name":"Division of Retina and Vitreous Diseases, Stein and Doheny Eye Institutes, University of California Los Angeles, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250714","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3345\/cep.2021.00773","article-title":"Retinopathy of prematurity: a review of epidemiology and current treatment strategies","volume":"65","author":"Hong","year":"2022","journal-title":"Clin Exp Pediatr"},{"key":"R2-20250714","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet"},{"key":"R3-20250714","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-20250714","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-20250714","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3928\/19382359-20171023-02","article-title":"Hot topics in retinopathy of prematurity","volume":"46","author":"Tsui","year":"2017","journal-title":"Pediatr Ann"},{"key":"R6-20250714","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ajo.2021.11.015","article-title":"Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity","volume":"238","author":"Gundlach","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R7-20250714","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"R8-20250714","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41433-021-01922-2","article-title":"The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity\u2014a current review","volume":"36","author":"Chow","year":"2022","journal-title":"Eye"},{"key":"R9-20250714","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"R10-20250714","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaapos.2014.03.011","article-title":"Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser","volume":"18","author":"Chen","year":"2014","journal-title":"J AAPOS"},{"key":"R11-20250714","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1097\/IAE.0000000000003875","article-title":"A multicenter study of retinopathy of prematurity follow-up adherence","volume":"43","author":"Mahmud","year":"2023","journal-title":"Retina"},{"key":"R12-20250714","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"R13-20250714","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"R14-20250714","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Good","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R15-20250714","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"R16-20250714","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"R17-20250714","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"R18-20250714","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-20250714","doi-asserted-by":"crossref","first-page":"5078565","DOI":"10.1155\/2017\/5078565","article-title":"Recurrence of retinopathy of prematurity in zone II stage 3+ after ranibizumab treatment: a retrospective study","volume":"2017","author":"Hu","year":"2017","journal-title":"J Ophthalmol"},{"key":"R20-20250714","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"R21-20250714","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/09286581003734860","article-title":"Incidence and risk factors of retinopathy of prematurity in Babol, North of Iran","volume":"17","author":"Ebrahim","year":"2010","journal-title":"Ophthalmic Epidemiol"},{"key":"R22-20250714","first-page":"219","article-title":"Retinopathy of prematurity in a tertiary care center-Incidence, risk factors and outcome","volume":"46","author":"Chaudhari","year":"2009","journal-title":"Indian Pediatr"},{"key":"R23-20250714","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","article-title":"Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs","volume":"115","author":"Gilbert","year":"2005","journal-title":"Pediatrics"},{"key":"R24-20250714","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","article-title":"Comparison in retreatments between bevacizumab and ranibizumab intravitreal injections for retinopathy of prematurity: a multicenter study","volume":"130","author":"Patel","year":"2023","journal-title":"Ophthalmology"},{"key":"R25-20250714","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T20:00:34Z","timestamp":1752523234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004206","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}